2022

UK NICE publishes Medtech Innovation Briefing on PromarkerD

New Constitution

Results of Meeting

AGM Chairman’s Address and Investor Presentation

PromarkerD patent granted in Hong Kong

Investor Presentation to the Emerging ASX Gems Conference

Proteomics International to present at the Emerging ASX Gems Conference

Quarterly Update September 2022 – Appendix 4C

Application for quotation of securities – PIQ

Change of Directors’ Interest Notices x2

Exercise of Director Options

Precision diagnostics facility receives $2m funding boost

Notice of Annual General Meeting/Proxy Form

Proteomics receives $1.7 million in R&D tax incentive

New Oesophageal Cancer Diagnostic shows strong performance

Annual Report to shareholders

Preliminary Final Report – Appendix 4E

Corporate Governance Statement and Appendix 4G

OxiDx launched to maximise oxidative stress technology

Proteomics raises $8m in successful Placement

Proteomics signs binding LOI with Sonic Healthcare USA

Clinical Utility Study demonstrates PromarkerD test benefits

Potential breakthrough blood test for endometriosis

Quarterly Update June 2022 – Appendix 4C

European PromarkerD patents expanded beyond diabetes

Investor Presentation

Exercise of Performance Rights

Application for quotation of securities – PIQ

Promarker™ pipeline – Endometriosis update Diagnostic readout positive: Study expanded

Proteomics International secures exclusive licence to oesophageal cancer biomarkers

PromarkerD manufacturing tech-transfer completed – Successful production of components for over 50,000 tests

Study shows PromarkerD ability to also predict late-stage kidney decline in type-2 diabetes patients

PromarkerD registration submitted to the TGA

Investor Presentation – Jefferies MedTech & Biotech summit

Proteomics International awarded $400,000 to support manufacturing capability in Australia

Quarterly Update March 2022 – Appendix 4C

New Clinical Advisory Board for PromarkerD global rollout

Investor Presentation – Perth Healthcare Summit

PromarkerD patent granted in India

Investor Presentation

Interim Financial Report & Appendix 4D

PromarkerD completes ‘pre-assessment’ for Medicare rebate

Novel biomarkers identified for Asthma and COPD

Unique panel of biomarkers identified for oesophageal cancer

Quarterly Update December 2021 – Appendix 4C